Waiver
Description:
CONSENT FOR RELEASE OF INFORMATION
Source:
training.aaap.org
Description:
The California Society of Addiction Medicine (CSAM) website provides information and materials for buprenorphine treatment providers, including screening tools and sample consent and patient agreement forms, and provides links to other helpful resources.
Source:
California Society of Addiction Medicine (CSAM)
Tags:
- General information - buprenorphine
- Getting a waiver/setting up your practice
- Initial patient contact
- Screening and diagnosis
- Rules, regulations and recordkeeping
- Physician and staff training
- Addiction
- Assessment
- Confidentiality
- Consent
- Contract
- COWS
- Recordkeeping
- Screening
- Training
- Waiver
- Misc. informational materials
- Becoming waivered
- Just became waivered
- Need to refer
- Setting up a practice
Description:
Information from the CSAT Buprenorphine Information Center on the criteria required to receive waiver under DATA 2000.
Source:
CSAT Buprenorphine Information Center
Tags:
Description:
This survey of 375 physicians found that confidence addressing drug problems was positively associated with having a buprenorphine waiver.
Source:
Journal of General Internal Medicine, 2007 (4 votes)
Description:
Instructions on how to complete and submit a waiver Notification of Intent form.
Source:
Substance Abuse and Mental Health Services Administration (SAMHSA) (3 votes)
Tags:
Description:
This is an online buprenorphine training course supported by the American Society of Addiction Medicine. Includes supplemental case studies.
Source:
Clinical Tools, Inc. (5 votes)
Tags:
Description:
Link to upcoming buprenorphine training events, both DATA and non-DATA qualifying.
Source:
Substance Abuse and Mental Health Services Administration (SAMHSA) (3 votes)
Tags:
Description:
This page links to the full text, summary, and physician waiver requirements under DATA 2000.
Source:
Substance Abuse and Mental Health Services Administration (SAMHSA) (3 votes)
Tags:
Description:
This form is for physicians to notify the DEA (through the Substance Abuse and Mental Health Services Administration) of their intent to use Schedule III, IV, or V drugs for treatment of opioid dependent patients.
Source:
The National Alliance of Advocates for Buprenorphine Treatment (NAABT) (3 votes)
Tags:
Description:
This is a training package developed by the Buprenorphine Awareness Blending Team to create awareness about buprenorphine among non-physician addiction professionals.
Source:
National Institute on Drug Abuse (NIDA) and The Addiction Technology Transfer Center (ATTC) (3 votes)
Tags:
